Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Molecular Partners
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
December 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
December 08, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
November 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
November 05, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
October 31, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
October 25, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
October 22, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
October 04, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
September 27, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
August 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
June 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
June 11, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
May 16, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
April 29, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Life Science Cares Launches in Switzerland
April 19, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2024
March 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
March 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
November 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
November 03, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.